AstraZeneca aims to fight Pfizer deal by burnishing its pipeline prospects

Up to now one of the only reasons any serious analyst could justify Pfizer's ($PFE) interest in AstraZeneca's ($AZN) pipeline centered on its early-stage work in immuno-oncology. But the U.K.'s Sky News city editor says that company is highlighting all its "hidden gems" in long-term development as evidence for investors to give Pfizer's $106 billion buyout offer a pass. Report